HK1190930A1 - Uses of aromatic-cationic peptide - Google Patents

Uses of aromatic-cationic peptide

Info

Publication number
HK1190930A1
HK1190930A1 HK14104163.7A HK14104163A HK1190930A1 HK 1190930 A1 HK1190930 A1 HK 1190930A1 HK 14104163 A HK14104163 A HK 14104163A HK 1190930 A1 HK1190930 A1 HK 1190930A1
Authority
HK
Hong Kong
Prior art keywords
aromatic
cationic peptide
cationic
peptide
Prior art date
Application number
HK14104163.7A
Other languages
English (en)
Chinese (zh)
Inventor
Hazel H Szeto
Kesheng Zhao
Peter W Schiller
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Publication of HK1190930A1 publication Critical patent/HK1190930A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
HK14104163.7A 2003-02-04 2014-04-30 Uses of aromatic-cationic peptide HK1190930A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44477703P 2003-02-04 2003-02-04
US53569004P 2004-01-08 2004-01-08

Publications (1)

Publication Number Publication Date
HK1190930A1 true HK1190930A1 (en) 2014-07-18

Family

ID=32853391

Family Applications (6)

Application Number Title Priority Date Filing Date
HK06112161.2A HK1090571A1 (en) 2003-02-04 2006-11-03 Methods for preventing mitochondrial permeability transition
HK09110947.4A HK1131995A1 (en) 2003-02-04 2006-11-03 Methods for preventing mitochondrial permeability transition
HK13105866.5A HK1178794A1 (en) 2003-02-04 2013-05-17 Methods for preventing mitochondrial permeability transition
HK14104163.7A HK1190930A1 (en) 2003-02-04 2014-04-30 Uses of aromatic-cationic peptide
HK15105970.6A HK1204999A1 (en) 2003-02-04 2015-06-23 Methods for preventing mitochondrial permeability transition
HK15110675.4A HK1209652A1 (en) 2003-02-04 2015-10-28 Uses of aromatic-cationic peptide

Family Applications Before (3)

Application Number Title Priority Date Filing Date
HK06112161.2A HK1090571A1 (en) 2003-02-04 2006-11-03 Methods for preventing mitochondrial permeability transition
HK09110947.4A HK1131995A1 (en) 2003-02-04 2006-11-03 Methods for preventing mitochondrial permeability transition
HK13105866.5A HK1178794A1 (en) 2003-02-04 2013-05-17 Methods for preventing mitochondrial permeability transition

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK15105970.6A HK1204999A1 (en) 2003-02-04 2015-06-23 Methods for preventing mitochondrial permeability transition
HK15110675.4A HK1209652A1 (en) 2003-02-04 2015-10-28 Uses of aromatic-cationic peptide

Country Status (14)

Country Link
US (8) US7576061B2 (xx)
EP (9) EP2491943B1 (xx)
JP (7) JP4838114B2 (xx)
CN (3) CN104225574B (xx)
AU (1) AU2004209663B2 (xx)
CA (1) CA2515080C (xx)
CY (2) CY1114959T1 (xx)
DK (3) DK2656854T3 (xx)
ES (3) ES2436011T3 (xx)
HK (6) HK1090571A1 (xx)
HU (1) HUE027110T2 (xx)
PT (2) PT2656854E (xx)
SI (1) SI2656854T1 (xx)
WO (1) WO2004070054A2 (xx)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2491943B1 (en) * 2003-02-04 2018-10-10 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
EP3167935B1 (en) 2003-05-01 2018-07-18 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
RU2376028C2 (ru) 2004-01-23 2009-12-20 Корнелл Рисеч Фаундейшн, Инк. Способ уменьшения окислительного повреждения (варианты)
AU2014203126B2 (en) * 2005-09-16 2016-03-10 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
CA2622911C (en) * 2005-09-16 2016-12-06 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
ES2458870T3 (es) 2008-02-07 2014-05-07 Cornell University Procedimientos para prevenir o tratar la resistencia a la insulina
EP3741381B1 (en) 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury
DE102008061044A1 (de) * 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
EP2408463B1 (en) * 2009-03-20 2016-10-19 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention and treatment of burn injuries and secondary complications
CN107412724A (zh) * 2009-08-12 2017-12-01 康奈尔大学 预防或治疗代谢综合症的方法
PT3708178T (pt) 2009-08-24 2023-11-16 Stealth Biotherapeutics Inc Peptídeo para uso ao prevenir ou tratar a degeneração macular
EP2944317A1 (en) * 2009-10-05 2015-11-18 Cornell University Methods for the prevention or treatment of heart failure
CA2786280A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
WO2011082328A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
JP2013518057A (ja) * 2010-01-25 2013-05-20 コーネル ユニヴァーシティー 芳香族カチオン性ペプチドおよびその使用
WO2011106717A1 (en) * 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP2808029A3 (en) * 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US20110245183A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245182A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
EP2942354A1 (en) * 2010-05-03 2015-11-11 Stealth Peptides International, Inc. Aromatic-Cationic Peptides and Uses of Same
CN106620645A (zh) * 2010-07-09 2017-05-10 康德生物医疗技术公司 预防或治疗缺血/再灌注损伤之后无复流的方法
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
WO2014137496A1 (en) * 2013-03-08 2014-09-12 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
US20120083452A1 (en) * 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
WO2012129427A2 (en) * 2011-03-24 2012-09-27 Cornell University Aromatic-cationic peptides and uses of same
JP2014527969A (ja) * 2011-09-19 2014-10-23 ジェンシア コーポレイション 改変クレアチン化合物
CA3123992C (en) * 2011-09-29 2024-06-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
CN107261380A (zh) * 2011-10-17 2017-10-20 康奈尔大学 芳香族阳离子肽及其用途
EP3009141A1 (en) * 2011-12-09 2016-04-20 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
AU2013237827B2 (en) * 2012-03-30 2017-12-14 Stealth Biotherapeutics Inc. Methods and compositions for the prevention and treatment neuropathy
CA2880648A1 (en) * 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
BR112015009072A2 (pt) * 2012-10-22 2017-07-04 Henry Ford Health Systems métodos para redução dos riscos associados à insuficiência cardíaca e fatores associados à mesma
WO2014134554A1 (en) * 2013-03-01 2014-09-04 Stealth Peptides International, Inc. Methods and compositions for the prevention or treatment of barth syndrome
CN116474071A (zh) * 2013-03-01 2023-07-25 康德生物医疗有限公司 治疗线粒体疾病的方法
EP2989120A4 (en) 2013-04-25 2017-04-19 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
WO2014209905A2 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods and compositions for detecting and diagnosing diseases and conditions
US20160193278A1 (en) * 2013-08-01 2016-07-07 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
CA2920020C (en) 2013-08-02 2023-03-14 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of friedreich's ataxia
US20160375088A1 (en) * 2013-09-30 2016-12-29 Brian Yinge ZHAO Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
EP3154694A1 (en) 2014-06-13 2017-04-19 Children's Medical Center Corporation Products and methods to isolate mitochondria
WO2015197723A1 (en) 2014-06-25 2015-12-30 Flamma S.P.A. Process for preparing d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
ES2890676T3 (es) 2014-06-30 2022-01-21 Flamma Spa Procedimiento para la producción de D-arginil-2,6-dimetil-L-tirosil-L-lisil-L-fenilalaninamida
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CN104306954B (zh) * 2014-09-25 2016-08-24 中山大学 Wry三肽在制备治疗阿尔茨海默症药物中的用途
EP3212194A4 (en) 2014-10-29 2018-06-20 University Of Maryland Methods of treating age-related symptoms in mammals and compositions therefor
WO2017015660A1 (en) * 2015-07-23 2017-01-26 Salk Institute For Biological Studies Prevention and treatment of aging and neurodegenerative diseases
WO2017093897A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
CN115160402A (zh) * 2016-03-11 2022-10-11 隐形生物治疗公司 结晶盐形式
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
WO2018100893A1 (ja) 2016-11-30 2018-06-07 株式会社ダイセル 撮像装置用レンズモジュール及びその製造方法
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
WO2019033330A1 (en) 2017-08-17 2019-02-21 Xw Laboratories, Inc. PREPARATION AND USES OF DERIVATIVES TRACERS OF OXYGEN REACTIVE SPECIES
JP6976618B2 (ja) 2017-09-04 2021-12-08 エックスダブリューファルマ リミテッド 活性酸素種スカベンジャーの調製および使用
JP6958860B2 (ja) * 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
US20220041653A1 (en) * 2018-12-18 2022-02-10 Stealth Biotherapeutics Corp. Mitochondria-targeting peptides
EP3962365A4 (en) * 2019-05-02 2023-02-01 Children's Medical Center Corporation THERAPEUTIC AND PROPHYLACTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIAL AGENTS
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
CA3191819A1 (en) 2020-09-09 2022-03-17 Hazel Szeto Methods and compositions for delivery of biotin to mitochondria

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
ES2085865T3 (es) 1988-06-30 1996-06-16 Astra Ab Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean.
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
ATE165208T1 (de) * 1990-01-17 1998-05-15 Univ California Zusammensetzung zur verbesserung der lebenserhaltung biologischer materialien
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
DE69630918T2 (de) * 1995-06-09 2004-10-28 Hisamitsu Pharmaceutical Co., Inc., Tosu Matrix für Iontophorese
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
DE69722258T2 (de) * 1996-10-07 2004-03-18 Eli Lilly And Co., Indianapolis Neue verbindungen nutlich als neuroschützende mittel
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6221355B1 (en) 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
US6268398B1 (en) * 1998-04-24 2001-07-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
GB9905503D0 (en) * 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
JP2003511362A (ja) * 1999-10-04 2003-03-25 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュー ジャージー 新規カルバメートおよび尿素類
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
EP1303186B1 (en) * 2000-07-18 2011-01-26 Cornell Research Foundation, Inc. Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
WO2002044126A2 (en) * 2000-11-28 2002-06-06 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and theirus
US6545097B2 (en) * 2000-12-12 2003-04-08 Scimed Life Systems, Inc. Drug delivery compositions and medical devices containing block copolymer
CA2435829A1 (en) * 2001-01-25 2002-08-01 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
AU2002247153A1 (en) * 2001-02-16 2002-09-04 Cordis Corporation Balloon catheter stent delivery system with ridges
AU2002252372A1 (en) * 2001-03-16 2002-10-03 Sts Biopolymers, Inc. Stent with medicated multi-layer hydrid polymer coating
JPWO2002102833A1 (ja) * 2001-06-15 2004-09-30 千寿製薬株式会社 新規エンドモルフィン誘導体
CN100536909C (zh) * 2003-02-04 2009-09-09 科内尔研究基金会 用于防止线粒体通透性改变的方法
EP2491943B1 (en) * 2003-02-04 2018-10-10 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
EP3167935B1 (en) 2003-05-01 2018-07-18 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
JP2005005762A (ja) * 2003-06-09 2005-01-06 Fujitsu Ltd 送信電力制御方法及び装置
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
RU2376028C2 (ru) * 2004-01-23 2009-12-20 Корнелл Рисеч Фаундейшн, Инк. Способ уменьшения окислительного повреждения (варианты)
CA2622911C (en) 2005-09-16 2016-12-06 Cornell Research Foundation, Inc. Methods for reducing cd36 expression

Also Published As

Publication number Publication date
CA2515080A1 (en) 2004-08-19
US20120021970A1 (en) 2012-01-26
EP1599216B9 (en) 2015-02-11
JP2019089773A (ja) 2019-06-13
EP1599216B1 (en) 2013-11-06
WO2004070054A3 (en) 2005-04-14
EP3305313A1 (en) 2018-04-11
EP2656854A1 (en) 2013-10-30
US8957030B2 (en) 2015-02-17
US20040248808A1 (en) 2004-12-09
US20100190718A1 (en) 2010-07-29
HK1209652A1 (en) 2016-04-08
AU2004209663A2 (en) 2004-08-19
WO2004070054A2 (en) 2004-08-19
PT1599216E (pt) 2013-12-17
CN102617706A (zh) 2012-08-01
EP1599216A2 (en) 2005-11-30
JP5775285B2 (ja) 2015-09-09
EP3479838A1 (en) 2019-05-08
JP4838114B2 (ja) 2011-12-14
JP2015007127A (ja) 2015-01-15
US20070027087A1 (en) 2007-02-01
JP2017095519A (ja) 2017-06-01
JP2006516652A (ja) 2006-07-06
US7718620B2 (en) 2010-05-18
EP2656854B1 (en) 2015-05-20
JP6166312B2 (ja) 2017-07-19
AU2004209663B2 (en) 2009-01-15
CN102784383B (zh) 2014-09-17
ES2436011T3 (es) 2013-12-26
CN104225574A (zh) 2014-12-24
HK1204999A1 (en) 2015-12-11
US20200038472A1 (en) 2020-02-06
JP2011026346A (ja) 2011-02-10
EP2491943A3 (en) 2013-01-23
PT2656854E (pt) 2015-09-03
ES2605504T3 (es) 2017-03-14
ES2540897T3 (es) 2015-07-14
US7576061B2 (en) 2009-08-18
JP2015180693A (ja) 2015-10-15
HK1178794A1 (en) 2013-09-19
EP2865385B1 (en) 2016-11-16
US8404646B2 (en) 2013-03-26
JP2013249313A (ja) 2013-12-12
AU2004209663A1 (en) 2004-08-19
EP2865385A1 (en) 2015-04-29
SI2656854T1 (sl) 2015-09-30
US20230293624A1 (en) 2023-09-21
CA2515080C (en) 2012-04-10
CN104225574B (zh) 2017-01-11
EP3842055A1 (en) 2021-06-30
EP2491943B1 (en) 2018-10-10
HK1090571A1 (en) 2006-12-29
EP3144009A1 (en) 2017-03-22
DK2656854T3 (en) 2015-07-06
JP5837542B2 (ja) 2015-12-24
DK1599216T3 (da) 2013-12-09
JP6126059B2 (ja) 2017-05-10
US20150359838A1 (en) 2015-12-17
US20130244957A1 (en) 2013-09-19
CY1114959T1 (el) 2016-12-14
EP2491943A2 (en) 2012-08-29
HK1131995A1 (en) 2010-02-12
EP3659618A1 (en) 2020-06-03
EP1599216A4 (en) 2009-11-11
DK2865385T3 (en) 2016-12-19
CY1116575T1 (el) 2017-03-15
HUE027110T2 (en) 2016-08-29
CN102784383A (zh) 2012-11-21

Similar Documents

Publication Publication Date Title
HK1209652A1 (en) Uses of aromatic-cationic peptide
IL172403A0 (en) D-amino acid peptides
GB0226251D0 (en) Acetylated protein
AU2003290563A8 (en) Leptin-related peptides
EP1578787A4 (en) NOVEL PEPTIDES OF CHI-CONOTOXIN (-II)
HK1090065A1 (en) Preparation of somatostatin peptides
GB0324265D0 (en) Peptide
EP1486507A4 (en) PEPTIDE INHIBITOR OF TRANSMEMBRANE NFAT
EP1614695A4 (en) POLYPEPTIDE
GB0324457D0 (en) Modified peptides and their uses
GB0202275D0 (en) Peptide
GB0203453D0 (en) Peptide synthesis
GB0205206D0 (en) Synthetic peptides
GB0210746D0 (en) Peptide
EP1699809A4 (en) PEPTIDE FROM AMNIOTIC LIQUID AND USES THEREOF
GB0312352D0 (en) Oxidation of peptides
GB0305552D0 (en) Purification of peptides
GB0322317D0 (en) Expansin polypeptide
GB0219980D0 (en) Peptides
GB2415195B (en) Peptides of IRF-1
GB0203883D0 (en) Peptide
GB0326303D0 (en) Peptides
GB0324466D0 (en) Peptides
GB0224896D0 (en) Peptides
GB0213246D0 (en) Peptides

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240202